GlassScriptPhysician profile
Bradley A Rubery
NPI 1235177270
$3,654.05
in general payments reported to CMS, 2019-2025
26 companies · $320 in 2025
The $320 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $334 · 2021: $648 · 2022: $655 · 2023: $366 · 2024: $699 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362 · Education: $23.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.11 |
| Education | $23.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,249.11 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $855.45 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $244.59 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $187.95 | 2019-2025 | Entyvio |
| Romark Laboratories, Lc | $151.72 | 2019-2020 | |
| Covidien LP | $100.45 | 2019 | |
| Ardelyx, INC. | $88.62 | 2024-2025 | Ibsrela |
| Celgene Corporation | $86.26 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.82 | 2019-2024 | Trulance |
| Celltrion USA INC. | $80.80 | 2024-2025 | Zymfentra, Vegzelma |
| Conmed Corporation | $72.17 | 2020-2024 | Conmed Biliary, Conmed Generators, Conmed Hemostasis |
| Phathom Pharmaceuticals, INC. | $67.30 | 2024 | Voquezna |
| Allergan, INC. | $47.29 | 2019 | |
| Genzyme Corporation | $45.61 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $45.34 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $38.74 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $30.85 | 2020-2021 | |
| Redhill Biopharma INC. | $28.79 | 2020-2021 | |
| Braintree Laboratories, INC. | $25.12 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $24.28 | 2021-2022 | |
| Qol Medical, LLC | $22.60 | 2019 | |
| Intra-Sana Laboratories | $17.79 | 2022 | |
| Shionogi INC | $17.31 | 2019 | |
| Axonics, INC. | $16.55 | 2024 | Axonics |
| Aimmune Therapeutics, INC. | $14.01 | 2024 | |
| Merck Sharp & Dohme LLC | $13.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Rubery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.